文献速递血栓与止血

在存在凝血因子VIII活性时对艾美赛珠单抗的功能性测定

Functional determination of emicizumab in presence of factor VIII activity.
PubMed 文献 · J Thromb Haemost · 2023-09-21

本研究评估血浆凝血因子VIII(FVIII)活性对艾美赛珠单抗测定值的影响,并比较三种校正或预分析抑制FVIII的策略:基于FVIII活性的数学计算、56°C加热40分钟、以及使用FVIII抑制物中和FVIII。加标实验显示FVIII活性与所测艾美赛珠单抗结果呈线性关联(约每IU/dL FVIII对应0.12 μg/mL),加热处理使患者样本内源性艾美赛珠单抗活性损失40%至50%,而抑制物中和法与液相色谱-串联质谱直接定量结果一致性良好。作者认为基于抑制物的FVIII中和似乎是存在FVIII活性时准确测定血浆艾美赛珠单抗水平的可行策略。

要点

  • FVIII活性会线性抬高艾美赛珠单抗测定值,约每IU/dL FVIII对应0.12 μg/mL。
  • 56°C加热40分钟使患者样本内源性艾美赛珠单抗活性损失40%至50%。
  • 基于抑制物的FVIII中和与液相色谱-串联质谱直接定量结果一致性良好。

核心结论

  • 作者认为基于抑制物的FVIII中和似乎是存在FVIII活性时准确测定血浆艾美赛珠单抗水平的可行策略。

研究设计与样本

  • 研究评估血浆FVIII活性对艾美赛珠单抗测定值的影响,并比较三种校正或预分析抑制FVIII的策略。
  • 策略包括基于所测FVIII活性与受FVIII影响的艾美赛珠单抗值计算实际血浆水平、56°C加热40分钟的预分析处理、以及使用FVIII抑制物中和FVIII活性。
  • 艾美赛珠单抗水平与FVIII活性分别采用改良FVIII一步法凝血试验和基于牛因子的发色底物FVIII试验测定。

主要发现

  • 加标实验显示在不同艾美赛珠单抗输入水平下,FVIII活性与所测受FVIII影响的艾美赛珠单抗结果之间呈一致的线性关联,约为每IU/dL FVIII对应0.12 μg/mL。
  • 患者样本经加热处理后观察到内源性血浆艾美赛珠单抗活性损失40%至50%,而加入FVIII缺乏血浆的艾美赛珠单抗未受影响或仅轻微受影响。
  • 应用基于抑制物的FVIII中和后,结果与液相色谱-串联质谱直接定量艾美赛珠单抗相比一致性良好。

临床怎么用

  • 作者认为基于抑制物的FVIII中和似乎是存在FVIII活性时准确测定血浆艾美赛珠单抗水平的可行策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate measurement of emicizumab in the presence of factor (F) VIII is required in patients with severe hemophilia A treated with emicizumab, as well as additional need for FVIII substitution or emicizumab prophylaxis in patients with acquired or moderate to mild hemophilia A. However, the presence of FVIII potentially biases the results. OBJECTIVES: To assess the impact of plasma FVIII activity on determined emicizumab levels and evaluate different strategies for correction for or preanalytical inhibition of FVIII. METHODS: Evaluated strategies comprised of the following: (1) calculation of actual emicizumab plasma levels based on measured FVIII activities and FVIII-affected emicizumab values, (2) preanalytical heat treatment (56 °C for 40 minutes), and (3) neutralization of FVIII activity using FVIII inhibitors. Emicizumab levels and FVIII activities were measured using a modified FVIII one-stage clotting assay and a chromogenic FVIII assay based on bovine factors, respectively. RESULTS: Spiking experiments revealed a consistent linear association between FVIII activities and determined (FVIII-affected) emicizumab results at different emicizumab input levels (∼0.12 μg/mL per IU/dL of FVIII). This principally allowed for mathematical correction of measured emicizumab levels in the presence of FVIII. While a 40% to 50% activity loss of intrinsic plasma emicizumab through heat treatment was observed in patient samples, emicizumab spiked into FVIII-deficient plasma was not or only marginally affected. Application of inhibitor-based FVIII neutralization led to good agreement of results when compared with direct quantification of emicizumab by liquid chromatography-tandem mass spectrometry. CONCLUSION: Inhibitor-based FVIII neutralization appears to be a feasible strategy for accurate measurement of plasma emicizumab levels in the presence of FVIII activity.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hamedani NS, Donners AAMT, van Luin M, et al. Functional determination of emicizumab in presence of factor VIII activity. J Thromb Haemost. 2023. PMID: 37741510. doi:10.1016/j.jtha.2023.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。